外周血管介入中血管内超声用于跛行未改善结局
基于Medicare和VISION两个队列,分析首次股腘动脉介入治疗跛行时使用血管内超声(IVUS)与长期结局的关联。Medicare队列中IVUS与更高的重复介入和进展为慢性肢体威胁性缺血风险相关,VISION队列中无显著差异。IVUS使用随时间快速增加,但无明确结局获益。
要点
- Medicare队列中IVUS与重复PVI风险升高相关(aHR 1.07,95%CI 1.02-1.12)。
- Medicare队列中IVUS与进展为CLTI风险升高相关(aHR 1.11,95%CI 1.03-1.20)。
- VISION队列中IVUS与非IVUS组结局无显著差异(P > 0.05)。
核心结论
- IVUS用于跛行治疗快速增加,但无明确结局获益,其在跛行治疗中的作用值得进一步研究。
研究设计与样本
- 两队列研究,使用2018-2022年100% Medicare按服务收费索赔数据和2016-2019年VISION数据。
- 纳入首次股腘动脉PVI治疗跛行的患者,排除CLTI和急性肢体缺血患者。
- 采用多变量Cox比例风险模型评估IVUS与重复PVI、进展为CLTI和截肢的关联,所有模型按医生聚类。
主要发现
- Medicare队列纳入69,092例患者(中位年龄74岁;女性40.5%;非西班牙裔黑人12.1%),其中22.1%(N=15,253)接受IVUS。
- VISION队列纳入6,722例患者(中位年龄72岁;女性38.7%;非西班牙裔黑人11.6%),其中3.8%(N=254)接受IVUS。
- 两队列平均随访时间均为2.7年,IVUS使用随时间显著增加,尤其在门诊手术中心/办公室实验室环境和联合斑块旋切术时(P < 0.001)。
- Medicare队列中,调整后IVUS与更高的重复PVI风险相关(aHR 1.07,95%CI 1.02-1.12)和进展为CLTI风险相关(aHR 1.11,95%CI 1.03-1.20)。
- VISION队列中,IVUS与非IVUS病例的结局无显著差异(均P > 0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出IVUS在跛行治疗中的作用值得进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The efficacy of intravascular ultrasound (IVUS) for improving outcomes of peripheral vascular interventions (PVIs) has not been well studied. We aimed to evaluate the association of IVUS with long-term outcomes in patients undergoing PVI for claudication. METHODS: We conducted a two-cohort study using data from 100% of Medicare fee-for-service claims (2018-2022) and the Vascular Quality Initiative Vascular Implant Surveillance and Interventional Outcomes Network (VISION; 2016-2019). For both cohorts, we identified all patients who underwent an index (first-time) femoropopliteal PVI for claudication, excluding patients with chronic limb-threatening ischemia (CLTI) and acute limb ischemia. We compared IVUS use over time and by procedure type and setting. We used multivariable Cox proportional hazards models to assess the associations of IVUS with repeat PVI, conversion to CLTI, and amputation. For the Medicare cohort, adjustments were made for baseline patient characteristics, while for the VISION cohort, additional adjustments were made for detailed anatomic factors. All models were clustered by physician. RESULTS: In the Medicare dataset, 69,092 patients (median age 74 years; 40.5% female; 12.1% non-Hispanic Black) underwent an index femoropopliteal PVI for claudication, of whom 22.1% (N = 15,253) received IVUS. In the VISION dataset, 6,722 patients (median age 72 years; 38.7% female; 11.6% non-Hispanic Black) underwent an index femoropopliteal PVI for claudication, of whom 3.8% (N = 254) received IVUS. The mean follow-up time for both cohorts was 2.7 years. For both the Medicare and VISION cohorts, IVUS use significantly increased over time, particularly in ambulatory surgery center/office-based laboratory settings and in conjunction with atherectomy procedures (P < 0.001). In the Medicare cohort, IVUS use was associated with a higher hazard of repeat PVI (adjusted hazard ratio [aHR] 1.07, 95% CI 1.02-1.12) and progression to CLTI (aHR 1.11, 95% CI 1.03-1.20) after adjustment compared to PVI without IVUS. In the VISION cohort, there were no significant differences in outcomes between IVUS and non-IVUS cases (all, P > 0.05). CONCLUSION: The use of IVUS for the treatment of claudication is rapidly increasing, without clear benefits in outcomes. The role of IVUS in treating claudication deserves further investigation.
引用
- Dun C, Weaver ML, Bose S, et al. Use of Intravascular Ultrasound during Peripheral Vascular Interventions for Claudication Is Not Associated with Improved Outcomes. Ann Vasc Surg. 2025. PMID: 40311752. doi:10.1016/j.avsg.2025.04.116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。